The NIH Almanac
The NIH Directors
NIH Director Francis S. Collins, M.D., Ph.D.
Francis S. Collins, M.D., Ph.D., a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the Human Genome Project, served as Director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health from 1993-2008. Read Dr. Collins' full biosketch
Chronology of NIH Directors
|Name||In Office from||To|
|Joseph J. Kinyoun1||August 1887||April 30, 1899|
|Milton J. Rosenau||May 1, 1899||September 30, 1909|
|John F. Anderson||October 1, 1909||November 19, 1915|
|George W. McCoy2||November 20, 1915
May 26, 1930
|May 25, 1930
Jan. 31, 1937
|Lewis R. Thompson||February 1, 1937||January 31, 1942|
|Rolla E. Dyer3||February 1, 1942
June 16, 1948
|June 15, 1948
September 30, 1950
|William H. Sebrell, Jr.||October 1, 1950||July 31, 1955|
|James A. Shannon||August 1, 1955||August 31, 1968|
|Robert Q. Marston||September 1, 1968||January 21, 1973|
|Robert S. Stone||May 29, 1973||January 31, 1975|
|Donald S. Fredrickson||July 1, 1975||June 30, 1981|
|James B. Wyngaarden||April 29, 1982||July 31, 1989|
|Bernadine Healy||April 9, 1991||June 30, 1993|
|Harold E. Varmus||November 23, 1993||December 31, 1999|
|Elias A. Zerhouni||May 2, 2002||October 31, 2008|
|Francis S. Collins||August 17, 2009||Present|
1 Director, Hygienic Laboratory.
2 Director, National Institute of Health.
3 Director, National Institutes of Health.
Joseph James Kinyoun, M.D.
Founder and director of the Hygienic Laboratory, Dr. Joseph J. Kinyoun introduced scientific research into the Marine Hospital Service. His interest in bacteriology and his isolation of the cholera organism laid the groundwork for the present health research program of NIH.
Dr. Kinyoun received his M.D. degree from New York University in 1882 and did postgraduate work in Europe under the German bacteriologist, Robert Koch.
Dr. Kinyoun joined the Marine Hospital Service in 1886. In a one-room laboratory on Staten Island, N.Y., he applied new techniques he had learned in Europe, enabling him to isolate the organism that causes cholera. The Hygienic Laboratory was established in August 1887 and Dr. Kinyoun served as its director until April 30, 1899.
During his government career, Dr. Kinyoun designed the Kinyoun-Francis sterilizer, a shipboard disinfecting apparatus. In 1903 he retired from public service and, after working in private industry and as a professor at the George Washington University, he became a bacteriologist in the District of Columbia Health Department.
Milton Joseph Rosenau, M.D.
As second director of the Hygienic Laboratory, Dr. Milton J. Rosenau was responsible for expanding its scope of investigations.
After receiving his M.D. from the University of Pennsylvania, he did postgraduate work in Europe in the field of sanitation and public health.
In 1890 he received his commission in the Marine Hospital Service. He became director of the Hygienic Laboratory on May 1, 1899.
A pioneer in the study of anaphylaxis, he also conducted research on yellow fever, malaria, typhoid fever, poliomyelitis, disinfectants, and the pasteurization of milk. His Preventive Medicine and Hygiene is a standard text for students of public health.
On September 30, 1909, Dr. Rosenau resigned from government service to join the staff of Harvard Medical School. In 1936 he went to the University of North Carolina where he served as director of the Public Health School.
John F. Anderson, M.D.
Dr. John F. Anderson, third director of the Hygienic Laboratory, was among the early scientists who made the Laboratory well-known in scientific circles.
After receiving his M.D. degree at the University of Virginia, he went abroad to study bacteriology. Upon returning in 1898, he joined the Marine Hospital Service and on October 1, 1909, succeeded Dr. Rosenau as director of the Hygienic Laboratory.
Throughout his career in the service, he was actively engaged in research. He studied serum and vaccine therapy, immunology, cholera, typhus, poliomyelitis, and public health and sanitation problems. He worked with Dr. Rosenau on hyper- susceptibility, anaphylaxis, and tuberculosis, and with Dr. Joseph Goldberger on the transmission of measles to monkeys, providing science with an experimental animal for that disease.
Dr. Anderson served as director of the Hygienic Laboratory until November 19, 1915, when he resigned to become director of the Research and Biological Laboratories and later vice president of E. R. Squibb & Sons.
George Walter McCoy, M.D.
Dr. George W. McCoy was, during his lifetime, the Nation's greatest authority on leprosy. For his many contributions to public health, he won the Sedgwick Memorial Medal of the American Public Health Association in 1921.
He entered the Marine Hospital Service in 1900 after graduating from the University of Pennsylvania Medical School.
During his first assignment at the Marine hospital in San Francisco, he became interested in leprosy. While heading the U.S. Plague Laboratory in San Francisco from 1908 to 1911, he discovered that the California ground squirrel was responsible for the spread of the organism causing tularemia.
On November 20, 1915, he became fourth director of the Hygienic Laboratory, renamed "National Institute of Health" in 1930. During this period he conducted important studies in influenza, poliomyelitis, smallpox, tularemia, amoebic dysentery, and pneumonia. Dr. McCoy served as director until January 31, 1937.
After conducting a nationwide survey on leprosy, Dr. McCoy retired from PHS on June 30, 1938, and joined the staff of Louisiana State University in New Orleans.
Lewis Ryers Thompson, M.D.
Dr. Lewis R. Thompson was intensely interested in research on industrial health problems and on problems of stream pollution.
He joined PHS in 1910, having graduated from Louisville Medical College. After becoming chief of the Division of Scientific Research in 1930, he administered field investigations of stream pollution, malaria, cancer, nutritional diseases, child hygiene, milk, dental problems, and industrial hygiene. When the division was merged with NIH, Dr. Thompson became director on February 1, 1937.
Dr. Thompson was largely responsible for securing the present-day site of NIH and for securing appropriations for the construction of the first six buildings. He served as director until January 31, 1942, and after retiring from PHS in 1947 became a scientific director of the international health division of the Rockefeller Foundation.
Rolla Eugene Dyer, M.D.
Dr. Rolla E. Dyer's major research contributions were in the field of infectious diseases; in particular, endemic typhus. He demonstrated how endemic typhus is spread and helped develop a vaccine to protect against the disease.
Dr. Dyer received his M.D. from the University of Texas and joined PHS in 1916.
His first assignment involved fieldwork on bubonic plague in New Orleans. Five years later he joined the staff of the Hygienic Laboratory, became chief of the Division of Infectious Diseases in 1936, and director of NIH in 1942.
As director, Dr. Dyer organized the Division of Research Grants, assisted in planning the Clinical Center, and helped establish three new institutes: the National Heart Institute, the National Institute of Dental Research, and the National Institute of Mental Health.
After retiring from active duty on September 30, 1950, Dr. Dyer served as a member of the scientific board of directors of the international health division of the Rockefeller Foundation.
William Henry Sebrell, Jr., M.D.
A leading international authority on nutrition, Dr. William H. Sebrell first recognized and described the dietary deficiency disease, ariboflavinosis, and made significant contributions to knowledge of dietary needs and deficiencies.
Dr. Sebrell received his M.D. degree from the University of Virginia and joined PHS in 1926.
He began his research career under Dr. Joseph Goldberger who demonstrated that pellagra is a deficiency disease. During the 1930's, Dr. Sebrell made many important contributions to our knowledge of the anemias and the role of diet in cirrhosis of the liver.
During World War II, Dr. Sebrell was codirector of the National Nutrition Program which coordinated activities of all state agencies working in the field of nutrition. This program aided food production and the maintenance of civilian health during the war years.
In 1948 he became director of the Experimental Biology and Medicine Institute, and on October 1, 1950, was appointed director of NIH. He held this post until his retirement on July 31, 1955.
Dr. Sebrell helped formulate the first international standards of nutrition for the League of Nations, and pioneered the growing acceptance of scientific nutrition as a regular function of modern state and local health departments.
James A. Shannon, M.D.
Dr. James A. Shannon, widely recognized in the scientific world for his original research in kidney function, chemotherapy, and malaria, has throughout his career, been devoted to medical research, teaching, and public service.
He received his M.D. in 1929 and a Ph.D. in physiology in 1935 from New York University.
Following his internship at Bellevue Hospital in New York, Dr. Shannon taught in the department of physiology at New York University College of Medicine from 1931 to 1941, and directed research at the university's Goldwater Memorial Hospital from 1940 to 1945.
During periods of leave, he served as guest investigator at the physiological laboratory, University of Cambridge, England, and as a member of the staff of the Marine Biological Laboratory at Woods Hole, Mass.
During World War II, Dr. Shannon played a prominent part in malaria research activities of the National Research Council and was consultant on tropical diseases to the secretary of war. In recognition of this work, he received the Presidential Medal for Merit, the highest award at that time for civilian service in government.
Before joining PHS in 1949, he was director of the Squibb Institute for Medical Research (1946-49), and special consultant to the PHS Surgeon General.
Dr. Shannon then served as associate director in charge of research in the National Heart Institute until 1952. After holding the post of associate director, NIH, for 3 years, he became its director on August 1, 1955.
Among his many honors were the Public Welfare Medal of the National Academy of Sciences for "eminence in the application of science to the public welfare" (1962), the Rockefeller Public Service Award for Science, Technology, or Engineering (1964), and the Presidential Distinguished Federal Civilian Service Award (1966).
On retiring as NIH director (August 31, 1968), Dr. Shannon joined the NAS as special advisor to the president. In February 1970 he became professor and special assistant to the president, Rockefeller University. He retired from those positions in 1975.
Robert Q. Marston, M.D.
Dr. Robert Quarles Marston became director of NIH on September 1, 1968, after serving for 5 months as administrator of the Health Services and Mental Health Administration.
He received his B.S. degree in 1943 from the Virginia Military Institute, and his M.D. from the Medical College of Virginia in 1947. As a Rhodes scholar, he worked for the next 2 years with Nobel prizewinner Howard Florey at Oxford University, Oxford, England, earning a B.Sc. from that institution in 1949.
After an internship at Johns Hopkins Hospital and a year's residency at Vanderbilt University Hospital in Nashville, Tenn., he was stationed at NIH from 1951 to 1953 as a member of the Armed Forces Special Weapons Project, conducting research on the role of infection after whole body irradiation. He completed his residency at the Medical College of Virginia in Richmond the following year.
While a Markle fellow, he served as assistant professor of medicine at the Medical College of Virginia from 1954 to 1957, and as assistant professor of bacteriology and immunology at the University of Minnesota in Minneapolis for 1 year. He returned to the Medical College of Virginia in 1959 as associate professor of medicine and assistant dean in charge of student affairs.
In 1961, Dr. Marston became director of the University of Mississippi Medical Center and dean of the School of Medicine in Jackson, Miss., and was appointed vice chancellor there in 1965.
He became an associate director of NIH and director of the newly created Division of Regional Medical Programs on February 1, 1966.
On April 1, 1968, Dr. Marston was named administrator of the Health Services and Mental Health Administration, under a departmental reorganization.
He became acting director of the National Institute of Neurological Diseases and Stroke on January 21, 1973. He left the Federal service in April 1973 to become a scholar-in-residence at the University of Virginia. He also was named the first distinguished fellow of the Institute of Medicine, NAS.
On January 11, 1974, Dr. Marston was named president of the University of Florida at Gainesville, a position he held until 1984, after which he sat on the governing board of Virginia Military Institute while continuing his work with graduate students at the University. He retired in the late 1980's.
Robert S. Stone, M.D.
Dr. Robert S. Stone, former vice president for health services and dean of the school of medicine at the University of New Mexico, became director of NIH on May 29, 1973.
He received his B.A. in 1942 from Brooklyn College and his M.D. from the State University of New York College of Medicine in 1950. Dr. Stone was an instructor in pathology at Columbia University College of Physicians and Surgeons from 1950 to 1952.
Following his 1950-1952 internship and assistant residency in pathology at New York's Presbyterian Hospital, Dr. Stone moved to Los Angeles and joined the faculty of UCLA's School of Medicine, department of pathology.
From 1957 to 1959 as part of his academic duties he was deputy coroner at Los Angeles County, and for several years was pathologist for the Los Angeles Shriners Hospital for Crippled Children.
While on sabbatical as a visiting scientist at the Rockefeller Institute in 1959, he was credited with demonstrating by electron microscopy that the Shope papilloma virus of rabbits could be found in mature skin cells, but was undetectable, although presumed present, in younger growing cells.
Based on his observation of autopsies of atomic bomb victims in Hiroshima, Japan, Dr. Stone was one of the first researchers to suggest that radiation exposure increases the incidence of certain known diseases rather than creating new types. He served as chief of research in pathology for the Atomic Bomb Casualty Commission from 1959 to 1960.
He contributed to the concept of developing a method control population to study the normal incidence of various diseases for comparison, as was subsequently done.
It was as a result of this work and his continuing interest that he was appointed to the NAS Advisory Committee on the Atomic Bomb Casualty Commission.
Dr. Stone joined the University of New Mexico School of Medicine as chairman of the department of pathology in 1963, and became dean of the school in 1968. Prior to his appointment as NIH director, he took a year's leave from the university and was a visiting professor at the Sloan School of Management, MIT.
He became dean of the School of Medicine of the University of Oregon Health Sciences Center and vice president of the Health Sciences Center in August 1975. In August of 1978, he was appointed dean of the College of Medicine at Texas A & M University in August of 1978.
Donald S. Fredrickson, M.D.
Dr. Donald S. Fredrickson, internationally known authority on lipid metabolism and its disorders, became NIH director on July 1, 1975. Immediately prior to this appointment, he had served for 1 year (1974-1975) as president of the Institute of Medicine, NAS.
His association with NIH, however, spanned more than two decades beginning in 1953 when he joined the scientific staff of the then National Heart Institute (renamed the National Heart, Lung, and Blood Institute in 1976) as a clinical associate.
During his research career in the Federal service, Dr. Fredrickson held numerous positions at NIH, several in the heart institute simultaneously. From 1955 to 1961 he was a member of the Laboratory of Cellular Physiology and Metabolism. He then served as clinical director (1961-1966), while continuing his research as head of the section of molecular diseases, Laboratory of Metabolism (1962-1966). He was appointed institute director in 1966, serving in that capacity until 1968. He combined this executive responsibility with research as chief of the Molecular Diseases Branch (1966-1974), and as director of intramural research (1969-1974).
His earliest research interests centered on the metabolism of sterols. Later he focused on the structure of the plasma lipoproteins, their importance in the transport of fats, and the genetic factors regulating their metabolism and concentration in blood. It was during this period that he discovered two new genetic disorders: Tangier disease (absence of high density lipoproteins) and cholesteryl ester storage disease, a lysosomal enzyme deficiency.
In 1965 he and his coworkers introduced a system for identifying and classifying blood-lipid abnormalities on the basis of plasma lipoprotein patterns. From this work came recognition of new monogenic causes of hyperlipidemia: type 3 and type 5 hyperlipoproteinemia and what is called familial hypertriglyceridemia. The system received prompt acceptance by the WHO and is now used widely by laboratories around the world.
Research findings of Dr. Fredrickson and colleagues have also included the discovery of several previously unknown apolipo-proteins, and new knowledge including descriptions concerning the structure and function of various apoproteins.
He received both his B.S. (1946) and M.D. (1949) from the University of Michigan, and was certified by the American Board of Internal Medicine in 1957. He did postgraduate work at Peter Bent Brigham and Massachusetts General Hospitals and the Harvard Medical School prior to coming to NIH in 1953.
Dr. Fredrickson was a member of numerous professional societies in addition to the NAS and the American Academy of Arts and Sciences.
He resigned as NIH director on June 30, 1981 and returned to the NAS as a visiting scholar. In 1983 he joined the Howard Hughes Medical Institute (HHMI) as vice president, and became president and CEO in 1984. In 1987 he left HHMI and became a scholar at the National Library of Medicine.
James B. Wyngaarden, M.D.
Dr. James B. Wyngaarden, an internationally recognized authority on the regulation of purine biosynthesis and the genetics of gout, and a nationally respected advisor on various aspects of the administration of biomedical research, became the 12th director on April 30, 1982. Immediately prior to his appointment, he was professor and chairman of the department of medicine at Duke University School of Medicine, a position he had held since 1967.
He has had a long association with the NIH. From 1953 to 1954, he was a research associate in the Laboratory of Chemical Pharmacology of the then National Heart Institute, and from 1954 to 1956, he was a clinical associate at the then National Institute of Arthritis and Metabolic Diseases. After leaving in 1956 to become associate professor at the Duke University School of Medicine, he continued an association with NIH. He has held grants from several NIH components.
Dr. Wyngaarden has been active on various NIH study groups, evaluation committees, and review panels over the years, including a term with the board of scientific counselors of the then NIAMD (1971-1974). He also served as a consultant to the NIH as a member of study sections (1958-1960; 1967-1969).
He has also served as advisor to the broader scientific community as a member of the National Academy of Sciences since 1974, and was active from 1975 to 1982 on an NAS committee set up to study the Nation's overall need for biomedical and behavioral researchers; consultant for the President's Office of Science and Technology (1966-1972), a member of the President's Science Advisory Committee (1972-1973), and a member of the U.S. Atomic Energy Commission's Advisory Committee on Biology and Medicine.
Dr. Wyngaarden is the coauthor of Cecil Textbook of Medicine. In collaboration with former NIH director, Dr. Fredrickson, and others, he edited The Metabolic Basis of Inherited Disease. The original work was published in 1960.
He attended Calvin College there, and Western Michigan University in 1943-1944. In 1948 he graduated first in his class from the University of Michigan Medical School.
Dr. Wyngaarden trained in internal medicine at the Massachusetts General Hospital and did postdoctoral work at the Public Health Research Institute of the City of New York, under the direction of Dr. DeWitt Stetten, Jr., former NIGMS director. After serving as research associate at NIH from 1953 to 1956, he went to Duke and in 1959 became director of the medical research training program there as well as associate professor of medicine and biochemistry. In 1961 he became professor of medicine and associate professor of biochemistry.
In 1963 and 1964, he was a visiting scientist at the Institute de Biologie-Physiocochemique in Paris. Shortly after his return to this country, he left Duke to become professor and chairman of the department of medicine and professor of biochemistry at the University of Pennsylvania. He returned to Duke in 1967.
Dr. Wyngaarden has received many honorary degrees: University of Michigan (D.Sc., 1980), Medical College of Ohio (D.Sc., 1984), University of Illinois at Chicago (D.Sc., 1985), George Washington University (D.Sc., 1986), and Tel Aviv University (Ph.D., 1987).
He is a diplomate of the American Board of Internal Medicine. He has served on editorial boards of numerous professional publications.
Dr. Wyngaarden is a member of a number of professional societies including the NAS Institute of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and is a past president of the Association of American Physicians. He is a fellow of the Royal College of Physicians of London and was elected to the Royal Academy of Sciences of Sweden in 1987.
Bernadine Healy, M.D.
Dr. Bernadine Healy became NIH director in April 1991. Shortly after her appointment, she launched the NIH Women's Health Initiative, a $500 million effort to study the causes, prevention, and cures of diseases that affect women. She also established the Shannon Award, grants designed to foster creative, innovative approaches in biomedical research and keep talented scientists in a competitive system.
Prior to her appointment, she was chairman of the Research Institute of the Cleveland Clinic Foundation, where she directed the research programs of nine departments including efforts in cardiovascular disease, neurobiology, immunology, cancer, artificial organs, and molecular biology. From her appointment in November 1985, she also served as a staff member of the clinic's department of cardiology.
In February 1984, Dr. Healy became deputy director of the Office of Science and Technology Policy at the White House. Her appointment, made by President Reagan and confirmed by the Senate in June of 1984, involved her heavily in life science and regulatory issues at the Federal level. She served as chairman of the White House Cabinet Working Group on Biotechnology, was executive secretary of the White House Science Council's Panel on the Health of Universities, and served as member of several advisory groups, including the councils of the NHLBI, NCI, as well as the White House Working Group on Health Policy and Economics. From June 1976 until February 1984, she was professor of medicine at Johns Hopkins University School of Medicine and Hospital, where she also had clinical responsibilities, directed a program in cardiovascular research, and was director of the coronary care unit. In addition to serving on the medical school faculty, she assumed the role of assistant dean for postdoctoral programs and faculty development.
Among her other professional affiliations, Dr. Healy has served on the board of governors of the American College of Cardiology and has been president of the American Federation of Clinical Research (1983-84) and was chairman of its public policy committee for several years. She was president of the American Heart Association in 1988-1989 and has served as a member of its board of directors since 1983. As AHA president, she initiated a women's minority leadership task force and a women and heart disease program that took hold in affiliates nationwide.
She is a member of the Institute of Medicine of NAS. In 1989 she was elected as a member of the board of overseers of Harvard College and has served on the board of trustees of Vassar College. She has also been chairman of the Ohio Council on Research and Economic Development, and served on several other advisory committees and boards, including the Ohio Board of Regents.
Dr. Healy has been active in several Federal advisory groups. Until her NIH appointment, she was a member of the advisory committee to the NIH director. She has been a member of the White House Science Council and chairman of the advisory panel for new developments in biotechnology of the Office of Technology Assessment of the U.S. Congress and a member of the NASA Life Sciences Strategic Planning Study Committee. In 1990 she was appointed to the President's Council of Advisers on Science and Technology (PCAST) and served as its vice chairman. She also chaired the advisory panel for basic research for the 1990s of the Office of Technology Assessment, and served on the special medical advisory committee of the Department of Veterans Affairs.
She received her bachelor's degree from Vassar College in 1965, and her M.D., cum laude, from Harvard Medical School in June 1970. She completed training in internal medicine and cardiology at Johns Hopkins School of Medicine.
Dr. Healy has written extensively in the areas of cardiovascular research and medicine, and has served on the editorial boards of numerous scientific journals.
She stepped down as director of NIH on June 30, 1993, to return to the Cleveland Clinic in Ohio. Dr. Healy was dean of the Ohio State University Medical School and President and Chief Executive Officer of the American Red Cross.
Harold E. Varmus, M.D.
Dr. Harold E. Varmus was nominated to become the 14th director of NIH by President William J. Clinton and was sworn in by HHS Secretary Donna Shalala on November 23, 1993. Winner of the Nobel Prize in 1989 for his work in cancer research (and the first Nobel Laureate to lead the NIH), his appointment was also notable for his lack of any prior administrative experience. Instead he was known at that time mainly for his scientific work at the University of California, San Francisco, where he had become a leader in the study of cancer-causing genes called "oncogenes" and an internationally recognized authority on retroviruses, the viruses that cause AIDS and many cancers in animals.
Prior to his appointment, he was professor of microbiology, biochemistry, and biophysics, and the American Cancer Society professor of molecular virology at UCSF, with an extensive history of interactions with the NIH. He had received his scientific training at an NIH Clinical Associate from 1968 to 1970 in the intramural laboratory of Dr. Ira Pastan, and during the next twenty–three years, he was a recipient of NIH career awards and grants, a member of an NIH Study Section, and a participant on NIH advisory committees.
Dr. Varmus and his UCSF colleague Dr. J. Michael Bishop shared the 1989 Nobel in Physiology or Medicine for demonstrating that cancer genes (oncogenes) can arise from normal cellular genes, called proto-oncogenes. While investigating a retroviral gene, v-src, responsible for the induction of sarcomas in chickens by Rous sarcoma virus, they discovered a cellular src gene, very similar to v-src, present in the normal cells of birds mammals, and all other animals. The c-src gene was the first example of cellular “proto-oncogenes” that can be activated by mutation to become cancer-causing genes; many of these genes are commonly mutated in human cancers and have become targets for new forms of cancer therapy.
Dr. Varmus’s scientific work before, during, and after his NIH Directorship has also included studies of retroviral replication; the development of mouse models of cancers; the discovery of the first mammalian Wnt genes; investigations of hepatitis B virus replication; and studies of the mechanisms of oncogene actions. His research activities have been supported by grants from NCI, NIAID, NIGMS, American Cancer Society, the NIH intramural program, and various philanthropies.
Prior to his appointment as NIH Director, Dr. Varmus served as chairman of the B oard on B iology for the National Research Council, an advisor to the Congressional Caucus for Biomedical Research, and a member of the Joint Steering Committee for Public Policy of Biomedical Societies. He directed "Winding Your Way Through DNA," a popular public symposium on recombinant DNA staged by UCSF. Dr. Varmus was also a member of the IOM committee that advised the Department of Defense on the use of funds allocated by Congress in 1992 for breast cancer research. In 1986 he chaired the subcommittee of the International Committee on the Taxonomy of Viruses that gave the AIDS virus its name, HIV.
Author or editor of five books and nearly 400 scientific papers, he has been elected to the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences. His 1992 book, Genes and the Biology of Cancer, coauthored with Robert Weinberg for the Scientific American Library, was intended for a general audience. A memoir published in 2009, The Art and Politics of Science (WW Norton), describes several aspects of his career as scientist, government official, and humanist, and is freely available through PubMed Central. He has also edited several professional journals, and served on a variety of review and advisory boards for government, biotechnology firms, and pharmaceutical companies.
He grew up on the south shore of Long Island, in Freeport, NY, where he attended public schools; his father practiced family medicine and his mother was a psychiatric social worker. He is a graduate of Amherst College (B.A., 1961), where he majored in English literature and edited the school newspaper; Harvard University (M.A., 1962) where he studied English literature as a Woodrow Wilson Fellow; and Columbia University (M.D., 1966). While in medical school, he worked for 3 months at a mission hospital in northern India.
After an internship and residency in internal medicine at Columbia-Presbyterian Hospital in New York, he served as a clinical associate for 2 years (1968-70) at the National Institute of Arthritis and Metabolic Diseases, where he did his first scientific work in the area of bacterial genetics with Dr. Ira Pastan, who is now co-chief of NCI's Laboratory of Molecular Biology. He went to UCSF initially as a postdoctoral fellow in Bishop's laboratory in 1970, developing a long-standing collaboration with Bishop to study tumor viruses, and was appointed to the faculty in 1971, becoming a full professor in 1979 and an ACS research professor in 1984.
During his tenure as Director of NIH, Dr. Varmus was noted for appointing several leading scientists to Directorships of Institutes and Centers; for overseeing the growth of the NIH budget from under $11 billion to over $18 billion, including the launch of a five year plan to double the NIH budget between 1998 to 2003; for planning the construction of the Mark O. Hatfield Clinical Research Center and the Dale and Betty Bumpers Center for Vaccine Reseach and completing the construction of the William Natcher Conference Center and the Louis Stokes Research Building; for nurturing multiple trans-Institute scientific initiatives; for supporting the accelerated growth of the Human Genome Project; for promoting research, especially on malaria, in developing countries; for conducting external evaluations of NIH research programs on HIV/AIDS and other topics; and for launching public access to full texts of NIH-supported research publications through the creation of PubMed Central. During his time as Director, he also attracted attention as a bicycle commuter (riding 12 miles to work through Rock Creek Park), as an active intramural scientist in the NCI program, and (through his work with the National Science and Technology Council) as a proponent of diverse sciences supported by many other US government agencies.
Dr. Varmus resigned from his position as NIH Director at the end of December 1999 to become the President and Chief Executive Officer of the Memorial Sloan-Kettering Cancer Center in New York City on the first day of 2000.
A Return to NIH
President Barack Obama appointed Dr. Varmus as the 14th Director of the National Cancer Institute, after he had served as President of MSKCC for ten and a half years and as co-Chair of President Obama’s Council of Advisors on Science and Technology; he was sworn in by HHS Secretary Kathleen Sebelius on July 12, 2010. A mong Dr. Varmus’ accomplishments during his tenure as NCI director, were the “Provocative Questions” initiative, the creation of NCI’s new Centers for Global Health and Cancer Genomics; completion of The Cancer Genome Atlas (an extensive study of nearly 10,000 cancer genomes from over twenty types of human cancer, in collaboration with the National Human Genome Research Institute); revitalization of the NCI’s clinical trials system; the restructuring of the NCI’s Frederick National Laboratory for Cancer Research and the launch of an FNLCR initiative to find drugs that target the cell signaling pathway controlled by the RAS oncogene; design of the cancer component of President Obama’s Precision Medicine Initiative; and changes in other aspects of the conduct of NCI-supported biomedical research, including a new Outstanding Investigator Award, grants to staff scientists, and an NIH biosketch that replaced the traditional bibliography with descriptions of major contributions to science. During this time, he continued his own research program in the NHGRI intramural program. Dr. Varmus stepped down on March 31, 2015, to join Weill Cornell Medical College's faculty as the Lewis Thomas University Professor in the Department of Medicine and the Meyer Cancer Center. At the same time, Dr. Varmus became a Senior Associate Core Member of the New York Genome Center (NYGC) to promote the use of cancer genomics throughout the New York region.
Elias A. Zerhouni, M.D.
Elias A. Zerhouni, M.D., was named the 15th NIH Director by President George W. Bush in May 2002 and led the nation’s medical research agency until October 2008.
Dr. Zerhouni, a world renowned leader in the field of radiology and medicine, spent his career providing clinical, scientific, and administrative leadership. He is credited with developing imaging methods used for diagnosing cancer and cardiovascular disease. As one of the world’s premier experts in magnetic resonance imaging (MRI), he had extended the role of MRI from taking snapshots of gross anatomy to visualizing how the body works at the molecular level. He pioneered magnetic tagging, a non-invasive method of using MRI to track the motions of a heart in three dimensions. He is also renowned for refining an imaging technique called computed tomographic (CT) densitometry that helps discriminate between non-cancerous and cancerous nodules in the lung. During his tenure as NIH Director, Dr. Zerhouni oversaw a number of milestones:
Reauthorization demonstrated renewed confidence in NIH
Congress passed and President Bush signed into law the National Institutes of Health Reform Act of 2006. The agency's third reauthorization in history and first since 1993, it signaled renewed confidence in the NIH mission, its employees, and its leadership.
Initiated the NIH Roadmap for Medical Research
In September 2003 Dr. Zerhouni launched a marquee initiative: The NIH Roadmap for Medical Research, a new research vision to accelerate medical discovery to improve health, immediately focused the attention of the biomedical research community on new pathways of discovery, research teams for the future, and the re-engineering of the clinical research enterprise.
Development of a new office to improve trans-NIH initiatives
In 2005, NIH launched a new office within the Office of the NIH Director to transform the way NIH finds and funds cutting-edge research; improve the ability to identify public health challenges; and increase trans-NIH dialogue, decision-making and priority-setting. The office built upon the model of the NIH Roadmap for Medical Research and increases coordination with NIH ICs and external stakeholders to identify research priorities that will ultimately improve NIH’s ability to be nimble, dynamic, and responsive to emerging scientific opportunities and public health needs.
The new entity, eventually named the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), provides an “incubator space” to jump-start trans-NIH initiatives and support Institutes and Centers that take the lead on priority projects on a time-limited basis (5 to 10 years). These initiatives are supported by a Common Fund.
Established an NIH-wide research initiative to address the obesity epidemic
The Strategic Plan for NIH Obesity Research addresses one of the nation’s most dramatic health changes with a multi-dimensional research agenda. The strategic plan enhances both the development of new research in areas of greatest scientific opportunity and the coordination of obesity research across the NIH. The plan called for interdisciplinary research teams to bridge the study of behavioral and environmental causes of obesity with the study of genetic and biologic causes.
Supported the NIH Neuroscience Blueprint
Mental illness, neurological disorders, and a range of behavioral disorders are major causes of human suffering and contribute greatly to the burden of disease. The blueprint leverages the abilities of the Institutes and Centers to create new resources, tackle common scientific problems, and train the next generation of neuroscientists through collaboration and leadership.
Made health disparities a research priority
Dr. Zerhouni’s commitment to eliminating health disparities and disparities in the burden of disease was evidenced by broadening the collaborative relationships developed through partnerships between NIH and institutions and researchers from all populations.
Ensured public access to NIH-funded research results
February 3, 2005, Dr. Zerhouni announced a historic public access policy. For the first time, the public gained access to peer-reviewed research publications that resulted from studies funded by NIH. Dr. Zerhouni urged maximum participation by investigators, encouraging scientists to submit their publications as soon as possible and within twelve months of publication to the accessible archive.
Dr. Zerhouni was committed to earning the public’s trust and sought advice from the Council of Public Representatives (COPR).COPR held the first ever public trust workshop to inventory and respond to public needs.
Prior to joining NIH, Dr. Zerhouni served as executive vice-dean of Johns Hopkins University School of Medicine, chair of the Russell H. Morgan department of radiology and radiological science, and Martin Donner professor of radiology, and professor of biomedical engineering. Before that, he was vice dean for research at Johns Hopkins.
Dr. Zerhouni’s imaging research has led to advances in Computerized Axial Tomography (CAT scanning) and Magnetic Resonance Imaging (MRI). It has earned him a Gold Medal from the American Roentgen Ray Society for CT research and two Paul Lauterbur Awards for MRI research. Dr. Zerhouni has also received the Special Presidential Award of the European Congress of Radiology.
From 1998–2002, he served on the National Cancer Institute’s Board of Scientific Advisors. He was a consultant to both the World Health Organization (1988) and to the White House under President Ronald Reagan (1985).
In April 2008, France bestowed its highest honor on Dr. Zerhouni. In a ceremony at Elysée Palace in Paris, French President Nicholas Sarkozy made him a Knight of the Légion d'honneur (French National Order of the Legion of Honor).
He has been a member of the Institute of Medicine since 2000.At the time Dr. Zerhouni left the NIH, he was the author of 212 publications and held 8 patents.